Early Breast Cancer Clinical Trial
Official title:
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer (EBC)
The trial will include pre and postmenopausal women and men with HR-positive, HER2-negative EBC, with an Anatomic Stage Group III, IIB or a subset of Stage IIA cases, after adequate surgical resection, radiotherapy (if indicated), adjuvant or neoadjuvant chemotherapy (if indicated), and who are deemed to be eligible for adjuvant ET for at least 60 months of duration. Approximately 5,000 patients will be randomized (using an Interactive Response Technology system [IRT]) into two treatment arms in a 1:1 ratio. The trial will include screening, treatment, and follow up phases. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04538833 -
GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
|
Phase 2 | |
Completed |
NCT04436744 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
|
Phase 2 | |
Completed |
NCT02187744 -
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
|
Phase 3 | |
Terminated |
NCT01155063 -
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03949634 -
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
|
Phase 3 | |
Active, not recruiting |
NCT05730647 -
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
|
||
Terminated |
NCT01919229 -
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
|
Phase 2 | |
Active, not recruiting |
NCT04293393 -
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
|
Phase 2 | |
Completed |
NCT00713141 -
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
|
N/A | |
Recruiting |
NCT06341894 -
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06435104 -
Aromatherapy in the Treatment of Early Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03520894 -
Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer
|
N/A | |
Completed |
NCT03786198 -
Activity Program During Aromatase Inhibitor Therapy
|
N/A | |
Completed |
NCT01613352 -
Feasibility of Ambulatory Surgery for Early Breast Cancer
|
N/A | |
Completed |
NCT02738970 -
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
|
Phase 1 | |
Recruiting |
NCT01792726 -
A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
|
N/A | |
Completed |
NCT00323479 -
Arthralgia During Anastrozole Therapy for Breast Cancer
|
Phase 4 | |
Completed |
NCT03493854 -
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
|
Phase 3 |